18,752 Shares in Roivant Sciences Ltd. (NASDAQ:ROIV) Bought by Impact Partnership Wealth LLC

Impact Partnership Wealth LLC purchased a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV) during the fourth quarter, according to its most recent filing with the SEC. The fund purchased 18,752 shares of the company’s stock, valued at approximately $222,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of ROIV. GAMMA Investing LLC raised its stake in Roivant Sciences by 57.0% during the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock valued at $42,000 after purchasing an additional 1,288 shares in the last quarter. Covestor Ltd increased its holdings in shares of Roivant Sciences by 9.1% in the 3rd quarter. Covestor Ltd now owns 19,190 shares of the company’s stock worth $222,000 after buying an additional 1,605 shares during the last quarter. US Bancorp DE raised its position in shares of Roivant Sciences by 146.5% during the 3rd quarter. US Bancorp DE now owns 3,278 shares of the company’s stock valued at $38,000 after buying an additional 1,948 shares in the last quarter. Quarry LP lifted its holdings in shares of Roivant Sciences by 50.0% in the 3rd quarter. Quarry LP now owns 7,500 shares of the company’s stock valued at $87,000 after acquiring an additional 2,500 shares during the last quarter. Finally, Gladius Capital Management LP purchased a new position in Roivant Sciences in the third quarter worth about $35,000. 64.76% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of Roivant Sciences in a research report on Wednesday, November 13th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $17.93.

Insider Transactions at Roivant Sciences

In other news, COO Eric Venker sold 100,000 shares of the firm’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $11.28, for a total transaction of $1,128,000.00. Following the transaction, the chief operating officer now owns 732,294 shares in the company, valued at approximately $8,260,276.32. This trade represents a 12.01 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Sciences Ltd. Roivant acquired 16,845,010 shares of the firm’s stock in a transaction that occurred on Monday, January 13th. The stock was purchased at an average price of $20.00 per share, with a total value of $336,900,200.00. Following the completion of the acquisition, the director now directly owns 96,650,341 shares of the company’s stock, valued at $1,933,006,820. This represents a 21.11 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 1,942,629 shares of company stock valued at $23,034,486. 7.90% of the stock is currently owned by company insiders.

Roivant Sciences Price Performance

Shares of ROIV opened at $11.17 on Friday. The firm has a market capitalization of $8.13 billion, a price-to-earnings ratio of 1.98 and a beta of 1.27. Roivant Sciences Ltd. has a 1-year low of $9.69 and a 1-year high of $13.06. The company has a 50-day moving average of $11.74 and a 200 day moving average of $11.60.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.